Journal of Ayurveda and Integrative Medicine最新文献

Background: Gestational Diabetes Mellitus (GDM) is a metabolic condition that develops in course of pregnancy. The World Health Organization describes it as carbohydrate intolerance that causes hyperglycemia of varying severity and manifests itself or is first noticed during pregnancy. Early prediction is now possible, owing to the application of cutting-edge methods like machine learning.

Objective: In the proposed empirical study, different machine-learning algorithms are applied to predict the prospective risk factors influencing the progression of GDM in gestating mothers.

Materials and methods: The performance of these algorithms is evaluated through accuracy, precision, f1-score, etc. The lifestyle interventions and medications listed in Ayurveda literature are discussed for effective management of the disease.

Results: Most of the proposed classifiers achieved a reasonable accuracy range of 75-82 %. Appropriate lifestyle changes, herbal remedies, decoctions, and churnas have all been shown to be useful in lowering the risk of GDM. Early detection using machine learning models can significantly reduce disease severity by facilitating timely Ayurvedic interventions.

Conclusion: The proposed work is more focused on the identification of factors impacting GDM in expectant women. A balanced diet with physical exercise, proper medication, and better lifestyle management (through Garbini Paricharya) can control the perils of GDM if diagnosed prematurely.

Ovarian cancer patients with BRCA1 mutation have more susceptibility for secondary breast cancer. In females with BRCA1 mutation, the risk of developing breast carcinoma is 65% and of ovarian cancer is 39%, before 70 years of age. This is a case report of a 74 year old, post-menopausal woman diagnosed with metastatic retroperitoneal lymph node, high-grade papillary adenocarcinoma primary ovary stage IIIA in April 2004 at the age of 48 years. She underwent 3 cycles of neo-adjuvant chemotherapy Inj. Methotrexate and Inj. Carboplatin from June to August 2004 followed by optimum cytoreduction in September 2004. Later she completed 3 more cycles of chemotherapy of the same protocol from October to November 2004. Tab Etoposide was given from December 2004 to October 2006. In May 2006, during oral chemotherapy and with unremarkable radiological findings, the patient chose Ayurvedic treatment in view of immune boosting, and improving quality of life. The patient underwent 11 sets of Panchakarma treatment, almost every year, from December 2007 to September 2019. She was disease-free for 13 years leading a good quality of life with adjunct Ayurvedic treatment. In October 2019, she was diagnosed with Left breast duct carcinoma with ER, PR hormone positive status. Her genetic mutation analysis report at that time revealed BRCA 1 mutation. She underwent Left Modified Radical Mastectomy in October 2019, followed by prophylactic Right Breast Mastectomy and oral hormonal therapy. Now she is living with better quality of life with adjunct Ayurvedic treatment, including Oral Ayurvedic Medicines possessing Rasayana (immunomodulatory) and hepato-protective activity and 12 sets of Panchakarma Chikitsa. In this case of Stage IIIA Ovarian carcinoma and second primary Breast carcinoma with BRCA 1 genetic mutation (HBOC syndrome), a long-term 13 years of disease-free survival, and 20 years of overall survival is achieved with the integration of Ayurvedic treatment and conventional cancer treatment.

Background: Xenografts in immunodeficient mice play a pivotal role in testing novel anti-cancer treatments. Xenograft models expedite the drug discovery process, offering a cost-effective alternative to conventional animal models and providing essential data for clinical trials. We have followed the approach described by the Developmental Therapeutics Program of the National Cancer Institute (NCI), USA to investigate the therapeutic responses.

Objectives: In this research, potentized preparations derived from biomaterial, referred to as nosodes, have exhibited promising effectiveness against cancer in laboratory experiments. This study seeks to further substantiate these findings by employing animal models.

Method: Potentized preparations from category nosodes sourced from biomaterials of HIV, Cancer tissue, Hepatitis C and a combination underwent testing within the NCI's preclinical evaluation protocols using Xenograft models (HOP62). All the experimental mice were randomly assigned to one of six groups (n = 6), including vehicle and positive controls. These preparations were administered orally at a dosage of 0.1 ml, five days a week, over a four-week period. The mice were closely monitored at regular intervals for 32 days, with observations regarding changes in body weight, tumor volume, morbidity, and mortality. Relative tumor volume (RTV) was calculated as the tumor volume on the day of measurement divided by the tumor volume on day 1.

Results: The groups treated with Hepatitis C 30c and HIV 100c nosodes have not shown effect with respect to Relative Tumor Volume (RTV). Evidence of significant tumor regression was observed for RTV on day 30 in groups treated with HIV nosode 30c (P = 0.002), and Cancer nosode 30c (P = 0.005). Percentage Survival was noted better in HIV nosode 30c treated group from day 25, however, in other groups survival percentage remained constant. Varied animal body weight in all groups was noted. Significant differences in tumor volume with respect to time in all treated groups were observed.

Conclusion: Results are suggestive of tumor regression which is encouraging to undertake further clinical trials to explore the anticancer potential of HIV nosode and Cancer nosode.